Evidence map›Paper›PMID 34646430›Full record

ArticleRare tumors2021

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.

Brian A Van Tine, Mia C Weiss, Angela C Hirbe, Peter J Oppelt, Sarah Abaricia, Kathryn Trinkaus, Jingqin Luo, Shellie Berry, Tyler Ruff, Cheryl Callahan and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rare tumors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Brian A Van TineDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.ORCID https://orcid.org/0000-0003-4572-6668
Mia C WeissDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Angela C HirbeDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.ORCID https://orcid.org/0000-0003-1719-0771
Peter J OppeltDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Sarah AbariciaDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Kathryn TrinkausDepartment of Biostatistics, Washington University in St. Louis, St. Louis, MO, USA.
Jingqin LuoDepartment of Biostatistics, Washington University in St. Louis, St. Louis, MO, USA.
Shellie BerryDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Tyler RuffDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Cheryl CallahanDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Jacqui ToensikoetterDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Jessica LeyDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Marilyn J SiegelSiteman Cancer Center, St. Louis, MO, USA.
Farrokh DehdashtiSiteman Cancer Center, St. Louis, MO, USA.
Barry A SiegelSiteman Cancer Center, St. Louis, MO, USA.
Douglas R AdkinsDivision of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Washington University in St. Louis · USSt. Louis Children's Hospital · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo · 2001 to 2026
$128.0M
NCI NIH HHS P30 CA091842
6 · The paper itself

Abstract

Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth factor support. In this single-arm, phase II study, dacarbazine 850 mg/m

Indexed as

bone sarcomadacarbazinenauseaPETSoft tissue sarcomavomiting

Identifiers

PMID34646430
PMCPMC8504645
OpenAlexW3205665086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.